Reduction of Transfusion Burden (TB), Hemoglobin Increase, and Dose Titration in the COMMANDS Study of Luspatercept Versus Epoetin Alfa (EA) in Erythropoietin-Stimulating Agent (ESA)-Naive Patients With Transfusion-Dependent (TD) Lower-Risk Myelodysplastic Syndromes (LR-MDS)

被引：0

作者：

Komrokji, Rami S. ^{[1
]}

Platzbecker, Uwe ^{[2
]}

Della Porta, Matteo ^{[3
,4
]}

Santini, Valeria ^{[5
]}

Garcia-Manero, Guillermo ^{[6
]}

Li, Jiahui ^{[7
]}

Zhang, Jennie ^{[7
]}

Giuseppi, Ana Carolina ^{[7
]}

Kreitz, Sandra ^{[8
]}

Pozharskaya, Veronika ^{[7
]}

Keeperman, Karen L. ^{[7
]}

Rose, Shelonitda ^{[7
]}

Hughes, Christina ^{[7
]}

Valcarcel, David ^{[9
]}

Fenaux, Pierre ^{[10
]}

Shortt, Jake ^{[11
,12
]}

机构：

[1] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA

[2] Dept Hematol Cell Hematol & Hemostaseol, Leipzig, Germany

[3] Canc Ctr IRCCS Humanitas Res Hosp, Milan, Italy

[4] Humanitas Univ, Dept Biomed Sci, Milan, Italy

[5] Univ Florence, AOUC, MDS Unit, Hematol, Florence, Italy

[6] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA

[7] Bristol Myers Squibb, Princeton, NJ USA

[8] Bristol Myers Squibb Co, Celgene Int Sarl, Boudry, Switzerland

[9] Hosp Univ Vall Hebron, Barcelona, Spain

[10] Univ Paris 07, Hop St Louis, Serv Hematol Seniors, Paris, France

[11] Monash Univ, Melbourne, Vic, Australia

[12] Monash Hlth, Melbourne, Vic, Australia

来源：

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2023年 / 23卷

关键词：

MDS; myelodysplastic neoplasms; erythroid response; clinical benefit; RBC transfusion independence; ESA-naive; phase III;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

MDS-234

引用

页码：S358 / S359

页数：2

共 31 条

[1] Efficacy and safety of luspatercept versus epoetin alfa (EA) in erythropoiesis-stimulating agent (ESA)-naive patients (pts) with transfusion-dependent (TD) lower-risk myelodysplastic syndromes (LR-MDS): full analysis of the COMMANDS trial
Platzbecker, Uwe
Garcia-Manero, Guillermo
Santini, Valeria
Zeidan, Amer M.
Fenaux, Pierre
Komrokji, Rami S.
Shortt, Jake
Valcarcel, David
Jonasova, Anna
Dimicoli-Salazar, Sophie
Tiong, Ing Soo
Lin, Chien-Chin
Li, Jiahui
Zhang, Jennie
Giuseppi, Ana Carolina
Kreitz, Sandra
Pozharskaya, Veronika
Keeperman, Karen L.
Rose, Shelonitda
Prebet, Thomas
Degulys, Andrius
Paolini, Stefania
Cluzeau, Thomas
Porta, Matteo Giovanni
ONCOLOGY RESEARCH AND TREATMENT, 2024, 47 : 243 - 243
[2] Efficacy and Safety of Luspatercept Versus Epoetin Alfa in Erythropoiesis-Stimulating Agent (ESA)-Naive Patients (Pts) with Transfusion-Dependent (TD) Lower-Risk Myelodysplastic Syndromes (LR-MDS): Full Analysis of the COMMANDS Trial
Garcia-Manero, Guillermo
Platzbecker, Uwe
Santini, Valeria
Zeidan, Amer M.
Fenaux, Pierre
Komrokji, Rami S.
Shortt, Jake
Valcarcel, David
Jonasova, Anna
Dimicoli-Salazar, Sophie
Tiong, Ing Soo
Lin, Chien-Chin
Li, Jiahui
Zhang, Jennie
Giuseppi, Ana Carolina
Kreitz, Sandra
Pozharskaya, Veronika
Keeperman, Karen L.
Rose, Shelonitda
Prebet, Thomas
Degulys, Andrius
Paolini, Stefania
Cluzeau, Thomas
Della Porta, Matteo Giovanni
BLOOD, 2023, 142
[3] Patient-Reported Outcomes (PRO) of Luspatercept Versus Epoetin Alfa in Erythropoiesis-Stimulating Agent (ESA)-Naive, Transfusion-Dependent (TD), Lower-Risk Myelodysplastic Syndromes (LR-MDS): Results from the Phase 3 COMMANDS Study
Oliva, Esther Natalie
Platzbecker, Uwe
Della Porta, Matteo Giovanni
Garcia-Manero, Guillermo
Santini, Valeria
Fenaux, Pierre
Shortt, Jake
Komrokji, Rami S.
Pelligra, Christopher
Guo, Shien
Lord-Bessen, Jennifer
Xiao, Hong
Yucel, Aylin
Miteva, Dimana
Rose, Shelonitda
Kreitz, Sandra
Sekeres, Mikkael A.
Zeidan, Amer M.
BLOOD, 2023, 142
[4] Efficacy and safety results from the COMMANDS trial: A phase 3 study evaluating luspatercept vs epoetin alfa in erythropoiesis-stimulating agent (ESA)-naive transfusion-dependent (TD) patients (pts) with lower-risk myelodysplastic syndromes (LR-MDS).
Garcia-Manero, Guillermo
Platzbecker, Uwe
Santini, Valeria
Zeidan, Amer Methqal
Fenaux, Pierre
Komrokji, Rami S.
Shortt, Jake
Valcarcel, David
Jonasova, Anna
Dimicoli-Salazar, Sophie
Tiong, Ing Soo
Lin, Chien-Chin
Li, Jiahui
Kreitz, Sandra
Pozharskaya, Veronika
Shetty, Jeevan K.
Degulys, Andrius
Finelli, Carlo
Cluzeau, Thomas
Della Porta, Matteo Giovanni
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[5] Treatment Patterns and Transfusion Outcomes Among Erythropoietin-Stimulating Agent (ESA)-Naive Patients With Lower-Risk Myelodysplastic Syndromes (LR-MDS) Receiving Luspatercept in Routine Clinical Practice in the United States (US)
Mukherjee, Sudipto
Brown-Bickerstaff, Cherrishe
Huggar, David
Falkenstein, Angelica
Makinde, Adeola Y.
Bland, Emily
Laney, JaLyna
Garretson, Marne
McBride, Ali
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S352 - S353
[6] RATIONALE FOR THERAPY DISCONTINUATION IN PATIENTS WITH LOWER-RISK TRANSFUSION-DEPENDENT MYELODYSPLASTIC SYNDROMES (LR-MDS)
Gerds, A. T.
Gupta, S.
Sekeres, M. A.
Nazha, A.
Carraway, H. E.
Hawthorne, S.
King-Concialdi, K.
McGuire, M.
LEUKEMIA RESEARCH, 2017, 55 : S140 - S141
[7] Clinical Benefits of Achieving Hemoglobin (Hb) Levels ≥ 10 g/dL in Transfusion-Dependent (TD) Erythropoiesis-Stimulating Agent (ESA)-Naive Patients (Pts) with Lower-Risk (LR) Myelodysplastic Syndromes (MDS) Treated with Luspatercept in the COMMANDS Trial
Santini, Valeria
Zeidan, Amer M.
Platzbecker, Uwe
Komrokji, Rami S.
Garcia-Manero, Guillermo
Miteva, Dimana
Yucel, Aylin
Pozharskaya, Veronika
Rose, Shelonitda
Lai, Yinzhi
Giuseppi, Ana Carolina
Ferreiras, David Valcarcel
Fenaux, Pierre
Shortt, Jake
Porta, Matteo Giovanni Della
BLOOD, 2024, 144 : 1818 - 1820
[8] Luspatercept Versus Epoetin Alfa (EA) for Treatment of Anemia in Patients With Erythropoiesis-Stimulating Agent (ESA)-Naive Lower-Risk Myelodysplastic Syndromes (LR-MDS) Requiring Red Blood Cell (RBC) Transfusions: Data from the Phase III COMMANDS Study
Garcia-Manero, Guillermo
Platzbecker, Uwe
Santini, Valeria
Zeidan, Amer M.
Fenaux, Pierre
Komrokji, Rami S.
Shortt, Jake
Valcarcel, David
Jonasova, Anna
Dimicoli-Salazar, Sophie
Tiong, Ing Soo
Lin, Chien-Chin
Li, Jiahui
Zhang, Jennie
Giuseppi, Ana Carolina
Kreitz, Sandra
Pozharskaya, Veronika
Keeperman, Karen L.
Rose, Shelonitda
Shetty, Jeevan K.
Hayati, Sheida
Vodala, Sadanand
Degulys, Andrius
Paolini, Stefania
Cluzeau, Thomas
Della Porta, Matteo
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S355 - S356
[9] Luspatercept versus epoetin alfa (EA) for treatment (tx) of anemia in ESA-naive lower-risk myelodysplastic syndromes (LR-MDS) patients (pts) requiring RBC transfusions (RBCT): data from the phase 3 COMMANDS study
Platzbecker, Uwe
Porta, Matteo Giovanni
Santini, Valeria
Zeidan, Amer M.
Fenaux, Pierre
Komrokji, Rami S.
Shortt, Jake
Valcarcel, David
Jonasova, Anna
Dimicoli-Salazar, Sophie
Tiong, Ing Soo
Lin, Chien-Chin
Li, Jiahui
Zhang, Jennie
Giuseppi, Ana Carolina
Kreitz, Sandra
Pozharskaya, Veronika
Keeperman, Karen L.
Rose, Shelonitda
Shetty, Jeevan K.
Hayati, Sheida
Vodala, Sadanand
Degulys, Andrius
Paolini, Stefania
Cluzeau, Thomas
Garcia-Manero, Guillermo
ONCOLOGY RESEARCH AND TREATMENT, 2024, 47 : 116 - 116
[10] Luspatercept Versus Epoetin Alfa for Treatment (Tx) of Anemia in Erythropoiesis-Stimulating Agent (ESA)-Naive Lower-Risk Myelodysplastic Syndromes (LR-MDS) Patients (pts) Requiring RBC Transfusions (RBCT): Data from the Phase 3 COMMANDS Study
Platzbecker, U.
Della Porta, M. G.
Santini, V.
Zeidan, A. M.
Fenaux, P.
Komrokji, R. S.
Shortt, J.
Valcarcel, D.
Jonasova, A.
Dimicoli-Salazar, S.
Tiong, I. S.
Lin, C. -C.
Li, J.
Zhang, J.
Giuseppi, A. C.
Kreitz, S.
Pozharskaya, V.
Keeperman, K. L.
Rose, S.
Shetty, J. K.
Hayati, S.
Vodala, S.
Degulys, A.
Paolini, S.
Cluzeau, T.
Garcia-Manero, G.
ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 16 - 17

← 1 2 3 4 →